0000000000610563

AUTHOR

Sandrine Katsahian

0000-0002-7261-0671

showing 3 related works from this author

Gender as a Modifying Factor Influencing Myotonic Dystrophy Type 1 Phenotype Severity and Mortality: A Nationwide Multiple Databases Cross-Sectional …

2016

International audience; BACKGROUND: Myotonic Dystrophy type 1 (DM1) is one of the most heterogeneous hereditary disease in terms of age of onset, clinical manifestations, and severity, challenging both medical management and clinical trials. The CTG expansion size is the main factor determining the age of onset although no factor can finely predict phenotype and prognosis. Differences between males and females have not been specifically reported. Our aim is to study gender impact on DM1 phenotype and severity.METHODS: We first performed cross-sectional analysis of main multiorgan clinical parameters in 1409 adult DM1 patients (\textgreater18y) from the DM-Scope nationwide registry and obser…

Male0301 basic medicineDatabases FactualPhysiologyCross-sectional studyMyotonic dystrophylcsh:MedicineDiseasecomputer.software_genreinfo:eu-repo/classification/mesh/Socioeconomic FactorsLaryngologyinfo:eu-repo/classification/mesh/Myotonic Dystrophy/epidemiology*0302 clinical medicineMedicine and Health SciencesEthnicitiesMedicineinfo:eu-repo/classification/mesh/FemaleFrench Peoplelcsh:Scienceinfo:eu-repo/classification/mesh/Adulteducation.field_of_studyMultidisciplinaryinfo:eu-repo/classification/mesh/Factual*Death ratesDatabaseCognitive NeurologyMortality rateDysphagia3. Good healthPhenotypeCognitive impairmentNeurologyPhysiological ParametersFemaleinfo:eu-repo/classification/mesh/Databasesinfo:eu-repo/classification/mesh/MaleResearch ArticleAdultMaternal inheritanceCognitive NeurosciencePopulation[SDV.GEN.GH] Life Sciences [q-bio]/Genetics/Human geneticsMyotonic dystrophy03 medical and health sciencesPopulation MetricsAdultsHumansObesitySex DistributioneducationDemographyinfo:eu-repo/classification/mesh/Cross-Sectional StudiesPopulation BiologyCataractsbusiness.industrylcsh:RBody WeightBiology and Life Sciencesmedicine.diseaseMyotoniaThyroid disorderinfo:eu-repo/classification/mesh/Sex DistributionHealth CareOphthalmologyCross-Sectional Studies030104 developmental biologyOtorhinolaryngologySocioeconomic Factors[SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human geneticsAge Groups[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieLens DisordersPeople and Placesinfo:eu-repo/classification/mesh/Myotonic Dystrophy/mortalityCognitive Sciencelcsh:QPopulation Groupings[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieHealth StatisticsMorbidityAge of onsetbusinessinfo:eu-repo/classification/mesh/Phenotype*computerinfo:eu-repo/classification/mesh/Humans030217 neurology & neurosurgeryNeurosciencePLOS ONE
researchProduct

Reduced-Dose Intravenous Thrombolysis for Acute Intermediate–High-risk Pulmonary Embolism: Rationale and Design of the Pulmonary Embolism Internation…

2021

Intermediate-high-risk pulmonary embolism (PE) is characterized by right ventricular (RV) dysfunction and elevated circulating cardiac troponin levels despite apparent hemodynamic stability at presentation. In these patients, full-dose systemic thrombolysis reduced the risk of hemodynamic decompensation or death but increased the risk of life-threatening bleeding. Reduced-dose thrombolysis may be capable of improving safety while maintaining reperfusion efficacy. The Pulmonary Embolism International THrOmbolysis (PEITHO)-3 study (ClinicalTrials.gov Identifier: NCT04430569) is a randomized, placebo-controlled, double-blind, multicenter, multinational trial with long-term follow-up. We will c…

medicine.medical_specialtypulmonary embolismVentricular Dysfunction Rightmedicine.medical_treatment2720 HematologyHemodynamicsHemorrhage610 Medicine & health030204 cardiovascular system & hematologyintermediate-high-risk; prognosis; pulmonary embolism; randomized trial; reduced-dose thrombolysis03 medical and health sciences0302 clinical medicineFibrinolytic AgentsInternal medicinemedicinerandomized trialHumansThrombolytic TherapyDecompensationStrokeHeparinbusiness.industry10031 Clinic for AngiologyHematologyThrombolysismedicine.diseasereduced-dose thrombolysis3. Good healthPulmonary embolismRegimenTreatment OutcomeBlood pressure030228 respiratory systemTissue Plasminogen ActivatorHeart failureAcute DiseaseCardiologyprognosisintermediate-high-riskbusiness
researchProduct

Evaluation of Internet Social Networks using Net scoring Tool: A Case Study in Adverse Drug Reaction Mining

2015

Suspected adverse drug reactions (ADR) reported by patients through social media can be a complementary tool to already existing ADRs signal detection processes. However, several studies have shown that the quality of medical information published online varies drastically whatever the health topic addressed. The aim of this study is to use an existing rating tool on a set of social network web sites in order to assess the capabilities of these tools to guide experts for selecting the most adapted social network web site to mine ADRs.First, we reviewed and rated 132 Internet forums and social networks according to three major criteria: the number of visits, the notoriety of the forum and th…

Drug-Related Side Effects and Adverse ReactionsPopulation SurveillanceAdverse Drug Reaction Reporting SystemsData MiningHumansReproducibility of Results[INFO]Computer Science [cs][INFO] Computer Science [cs]Sensitivity and SpecificitySocial MediaSoftware
researchProduct